**1. Introduction**

336 Autoimmune Disorders – Current Concepts and Advances from Bedside to Mechanistic Insights

Thacker, H. (2010). Glucocorticoid-induced osteoporosis. *Cleve Clin J Med*, Vol.77, No.12, Dec

Trousson, A., Makoukji, J., Petit, P.X., et al. (2009). Cross-talk between oxysterols and

Ullian, M.E. (1999). The role of corticosteriods in the regulation of vascular tone. *Cardiovasc* 

Van den Hove, D.L., Steinbusch, H.W., Bruschettini, M., et al. (2006). Prenatal stress reduces

Vardimon, L., Ben-Dror, I., Avisar, N., et al. (1999). Glucocorticoid control of glial gene

Vielkind, U., Walencewicz, A., Levine, J.M., et al. (1990). Type II glucocorticoid receptors are

Wolkowitz, O.M. (1994). Prospective controlled studies of the behavioral and biological

Xu, J., Chen, S., Chen, H., et al. (2009). STAT5 mediates antiapoptotic effects of

Zschocke, J., Bayatti, N., Clement, A.M., et al. (2005). Differential promotion of glutamate

brain regions. *J Biol Chem*, Vol.280, No.41, Oct 14 2005, pp. (34924-32).

oligodendrocyte death. *PLoS One*, Vol.4, No.11, 2009, pp. (e8080).

expression. *J Neurobiol*, Vol.40, No.4, Sep 15 1999, pp. (513-27).

2009, pp. (753-89).

(1077-80).

1990, pp. (360-73).

pp. (233-55).

(2022-6).

2010, pp. (843; author reply 843-4).

*Res*, Vol.41, No.1, Jan 1999, pp. (55-64).

adrenal axis function in humans: a systematic review. *Endocr Rev*, Vol.30, No.7, Dec

glucocorticoids: differential regulation of secreted phopholipase A2 and impact on

S100B in the neonatal rat hippocampus. *Neuroreport*, Vol.17, No.10, Jul 17 2006, pp.

expressed in oligodendrocytes and astrocytes. *J Neurosci Res*, Vol.27, No.3, Nov

effects of exogenous corticosteroids. *Psychoneuroendocrinology*, Vol.19, No.3, 1994,

methylprednisolone on oligodendrocytes. *J Neurosci*, Vol.29, No.7, Feb 18 2009, pp.

transporter expression and function by glucocorticoids in astrocytes from various

Over the last decade, high-dose polyclonal intravenous immunoglobulin (IVIg) is used increasingly in the management of autoimmune conditions of the central and peripheral nervous system. Despite the expanded use of IVIg, the consensus on its optimal use is insufficient. Currently chronic idiopathic demyelinating polyneuropathy (CIDP), Guillain – Barre syndrome (GBS) and multifocal motor neuropathy (MMN) are the three major immune neuropathies, in which the latest evidence strongly supports the use of IVIg as a first-line therapy. In addition to these disorders, there is a rising number of other neurological indications in which IVIg has been used as a therapy, even though the available evidence-based data are relatively sparse and less convincing. Due to increasing costs of this treatment and relative shortage of products, careful selection of patients who will benefit from IVIg is extremely important (Elovaara & Hietaharju, 2010).

In this paper the current literature on the use of IVIG in treatment of neurological diseases has been reviewed and evidence-based recommendations, as well as less convincing data and future possibilities for its use in these disorders are presented.
